InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Core Insights - InMed Pharmaceuticals has successfully completed pharmacokinetic studies in large animal models for its Alzheimer's disease candidate INM-901, marking a significant step towards human clinical trials [1][2][3] Pharmacokinetic Study Results - The oral formulation of INM-901 demonstrated robust bioavailability over a seven-day dosing period, achieving therapeutic levels of systemic exposure, which supports its potential use in treating neurodegenerative disorders like Alzheimer's disease [3][4] - Neurological assessments showed no adverse neural or behavioral effects, reinforcing the compound's favorable safety profile [4][6] Development and Regulatory Preparation - InMed has advanced its chemistry, manufacturing, and controls (CMC) development to scale up the manufacturing process of INM-901 in preparation for Investigational New Drug (IND)-enabling studies and regulatory interactions with the FDA [5][10] - The company is preparing for a pre-IND meeting with the FDA and conducting dose-ranging studies in two species to support IND submission [9][10] Company Overview - InMed Pharmaceuticals focuses on developing proprietary small-molecule drug candidates targeting CB1/CB2 receptors, with a pipeline that includes programs for Alzheimer's, ocular, and dermatological indications [11]